The efficacy and safety of subcutaneous immuno-therapy with dermatophagoides pteronyssinus for allergic rhinitis.
- Author:
Jun LIU
1
;
Jing WAN
;
Yi ZHOU
;
Zhong LIU
Author Information
1. Department of Otorhinolaryngology Head and Neck Surgery, Central Hospital of Enshi, Enshi, 445000, China. dalia00589@163.com
- Publication Type:Journal Article
- MeSH:
Allergens;
therapeutic use;
Animals;
Dermatophagoides pteronyssinus;
immunology;
Female;
Humans;
Immunotherapy;
methods;
Male;
Rhinitis, Allergic;
therapy
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2012;26(11):510-512
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the efficacy and safety of subcutaneous immunotherapy with a standardized Dermatophagoides pteronyssinus extract for allergic rhinitis.
METHOD:Sixty-eight patients with allergic rhinitis who received specific immunotherapy with a standardized dermatophagoides pteronyssinus extract were enrolled in this study. The clinical symptoms and signs were scored before and 2 years after treatment. Side effects were registered. Symptom and side effect scores were assessed to evaluate the clinical efficacy and safety.
RESULT:There was a significant difference (P < 0.01) in symptom and medication scores between the two groups tow years after treatment. The patients had fewer symptoms and lower intake of medication. No severe systemic reactions were registered.
CONCLUSION:Immunotherapy with a standardized dermatophagoides pteronyssinus extract is effective and safe to treat patients clinically sensitive to this allergen.
